It’s been suggested that the newly confirmed Secretary of HHS, Xavier Becerra, poses a greater threat than his predecessor, Alex Azar, to the pharmaceutical industry. Becerra is likely, however, to focus his attention more broadly on anti-competitive practices throughout the healthcare system.